1. Home
  2. SINT vs PCSA Comparison

SINT vs PCSA Comparison

Compare SINT & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SINT
  • PCSA
  • Stock Information
  • Founded
  • SINT 1996
  • PCSA 2011
  • Country
  • SINT United States
  • PCSA United States
  • Employees
  • SINT N/A
  • PCSA N/A
  • Industry
  • SINT Medical/Dental Instruments
  • PCSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SINT Health Care
  • PCSA Health Care
  • Exchange
  • SINT Nasdaq
  • PCSA Nasdaq
  • Market Cap
  • SINT 11.6M
  • PCSA 12.0M
  • IPO Year
  • SINT 2014
  • PCSA N/A
  • Fundamental
  • Price
  • SINT $3.30
  • PCSA $0.31
  • Analyst Decision
  • SINT Strong Buy
  • PCSA Strong Buy
  • Analyst Count
  • SINT 1
  • PCSA 1
  • Target Price
  • SINT $25.00
  • PCSA $1.00
  • AVG Volume (30 Days)
  • SINT 411.0K
  • PCSA 6.0M
  • Earning Date
  • SINT 11-13-2025
  • PCSA 11-06-2025
  • Dividend Yield
  • SINT N/A
  • PCSA N/A
  • EPS Growth
  • SINT N/A
  • PCSA N/A
  • EPS
  • SINT N/A
  • PCSA N/A
  • Revenue
  • SINT $1,861,000.00
  • PCSA N/A
  • Revenue This Year
  • SINT N/A
  • PCSA N/A
  • Revenue Next Year
  • SINT $80.00
  • PCSA N/A
  • P/E Ratio
  • SINT N/A
  • PCSA N/A
  • Revenue Growth
  • SINT N/A
  • PCSA N/A
  • 52 Week Low
  • SINT $1.71
  • PCSA $0.15
  • 52 Week High
  • SINT $8.60
  • PCSA $1.50
  • Technical
  • Relative Strength Index (RSI)
  • SINT 42.72
  • PCSA 48.37
  • Support Level
  • SINT $3.03
  • PCSA $0.31
  • Resistance Level
  • SINT $3.53
  • PCSA $0.41
  • Average True Range (ATR)
  • SINT 0.30
  • PCSA 0.04
  • MACD
  • SINT -0.01
  • PCSA -0.01
  • Stochastic Oscillator
  • SINT 34.20
  • PCSA 24.17

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: